Vasoxyl

NDA 6772, held by Glaxosmithkline. Methoxamine Hydrochloride.

As of Nov 13, 2026, NDA 6772 (Vasoxyl), held by Glaxosmithkline, was first approved by FDA on Mar 28, 1949, with 3 approved supplements and 0 published complete response letters.

First approved: Mar 28, 1949
Supplements approved: 3
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 4 submissions below

Date	Submission	Status	Documents
Mar 28, 1949	Original application	Approved	None posted

Products

2 strengths and forms


Vasoxyl20MG/ML · injectable;injection	Methoxamine Hydrochloride	Discontinued
Vasoxyl10MG/ML · injectable;injection	Methoxamine Hydrochloride	Discontinued

All 4 submissions, including labeling and manufacturing supplements


Sep 17, 2001	Supplement 3Labeling	Approved	None posted
May 15, 1987	Supplement 6Labeling	Approved	None posted
Oct 1, 1986	Supplement 5Labeling	Approved	None posted
Mar 28, 1949	Original application	Approved	None posted

Identifiers

Application: NDA 6772
Drugs@FDA: Overview at FDA
Company: GlaxoSmithKline LLC

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters